The Trump administration continues to push for lower drug prices and domestic pharmaceutical manufacturing, with Special Adviser Calley Means reaffirming the stance at a US pharma summit in New York.
Means emphasized that the goal isn’t to set prices directly, but to align US drug costs with those in other developed countries. “We just don’t want to pay more,” he said, calling threats by firms like Roche to pull manufacturing investments “morally reprehensible.”
Trump recently signed a Most Favored Nation executive order that would require drug prices in the US to match the lowest price offered in any developed country. The move follows previous initiatives that already inspired over $100 billion in onshoring commitments from companies like Roche, Johnson & Johnson, and Eli Lilly.
Despite some support, concerns remain. AstraZeneca warned the policy could disrupt patient care and stifle innovation, while Eli Lilly’s CEO urged Trump to “declare victory and move on.”